Daewoong Pharmaceutical said it will partner with KB Biomed to develop an oral treatment for osteoporosis.
On Friday, Daewoong announced that it had signed a joint development and licensing agreement with KB Biomed for synthetic or recombinant peptides of teriparatide, an osteoporosis drug. The two companies plan to develop the existing teriparatide injection as an incrementally modified oral drug (IMD).
Under the agreement, the two companies will maintain close cooperation to manufacture oral teriparatide, from developing a formulation to conducting clinical trials and commercializing it, Daewoong said.
KB Biomed will develop an oral formulation and conduct preclinical trials, and Daewoong will handle formulation development, manufacturing process development, preclinical trials, global trials and commercialization. In addition, the two companies will share new intellectual property rights.
KB Biomed was founded in 2012 by CEO Lee Yong-kyu, who also works as a professor at Korea National Transportation University.
The company has a technology to transform an injection drug into an oral drug thanks to an innovative platform. As the platform can be applied to all gene-based drugs, peptides and chemicals, KB Biomed conducts joint research and projects with various companies and researchers.
Teriparatide is a recombinant human parathyroid hormone (PTH) that acts like a parathyroid hormone in the body. As a promoter of osteogenesis, it treats osteoporosis.
Teriparatide shows excellent effects on both men and women, but the drug is only available in injection form. The treatment is very expensive and causes many side effects. It is used on a limited basis in patients who cannot receive a bone resorption inhibitor or those who are at high risk of fractures.
In chronic diseases such as osteoporosis, it is important to improve patient comfort for the drug. If oral teriparatide is marketed, it will give patients better access to the drug, Daewoong said.
“We are delighted to partner with KB Biomed, which has an innovative platform to manufacture oral treatments from many drugs,” said Jeon Seng-ho, CEO of Daewoong Pharmaceutical. “Through this agreement, we will accelerate the discovery of oral therapeutics for the convenience of administration for patients with osteoporosis.”